Attention Deficit Hyperactivity Disorder (ADHD) affects a significant part of the population and causes considerable behavioural problems, learning limitations in the context of the formal education system and increased chances for social exclusion. Current treatment approaches induce high costs to welfare systems and individuals, while the widespread usage of stimulant medication remains a subject of controversy due to undesirable side-effects. FocusLocus brings together a multidisciplinary Consortium of partners aiming to design and produce market-oriented products and services for ADHD management by leveraging knowledge and technology from previous research and innovation activities. FocusLocus proposes a highly disruptive and innovative game-based intervention, relying on agent-based game mechanics that incorporate learning schemes for mental and motor skill acquisition and behavioural change, adopting multisensory user interaction, featuring personalisation, adaptation, performance analytics and monitoring features, delivered in a dual User Experience (UX) mode. Even though FocusLocus will be designed, tested and evaluated specifically for the case of ADHD management, it is expected that it will also be beneficial to a number of other associated mental, psychological and cognitive disorders and learning disabilities, thus generating a substantial marketing potential. FocusLocus activities will include the deployment of a pilot study for the extensive assessment of the proposed gaming system, the generation of evidence regarding its performance, the documentation of results for further ADHD research purposes and the creation of solid foundations for a marketable product.

Cortechs is addressing an exponentially growing brain-based health challenge impacting over 2 billion people and 1 in 9 children worldwide: the inability to reach the basic cognitive skill levels needed to maintain the attention needed for school, work, home and life. Cortechs create data-driven, therapeutic games that improve attention levels in children. ADHD is expensive, it causes suffering and it impairs social and lifelong productivity for the child and their family. Each task a child partakes in needs their full attention to be performed successfully. While this statement may seem obvious, the reality is that current EU-wide approaches to treat these symptoms come at extortionate costs (trillions pa) to the European health and welfare systems with medication alone not tackling the core, cognitive skills affected in ADHD. Our intervention provides games which can be played using your brainwaves on smart devices. Progress data can be remotely assessed by specialist clinicians to prescribe and amend individual therapies on secure web dashboards. Cortechs neurofeedback platform and gaming delivery system is a highly innovative, consumer facing solution in the cognitive healthcare market for ADHD. Therapeutics in cognitive impairments (CI) is a high-volume market valued at €80 billion and will grow to €393 billion market by 2022. Our Cortechs enterprise platform (called Cerebrill) applies key evidence-based ADHD treatments in an end-to-end digital solution with access to easy-to-use, engaging smart brainwave games to improve their behaviours. The solution is device agnostic, cheaper and accessible anywhere with prescriptives remotely and securely controlled and moderated by clinicians. This proposal would enable Cerebrill to be speedily commercialised to enterprise alongside a regulatory clinical validation process so Cortechs can offer Cerebrill as a therapy for improving attention symptoms in the ADHD healthcare space within 24 months.